Bacterial Vaccines and Therapies - Building a Product Pipeline

Absynth Biologics已成功展示了一种开发新型抗菌疫苗和抗体的创新方法。Absynth的技术鉴定了蛋白质，这些蛋白质是控制免疫系统的细菌生命所必需的。到目前为止，该公司已经证明其方法可以防止主要病原体金黄色葡萄球菌（S.aureus），包括抗生素耐药变种MRSA（甲氧西林耐药S. aureus)具有良好的抗菌活性。Absynth抗金黄色葡萄球菌疫苗和抗体的临床前开发正在取得进展，Absynth技术的一个核心方面是这些蛋白在细菌界的保守程度。因此，在S.金黄色葡萄球菌也存在于许多其它细菌病原体中。有了这些专有知识，Absynth可以迅速启动新的疫苗和抗体项目，开发产品线。本项目的目标是评估更广泛的市场需求，以预防和治疗细菌感染，可通过Absynth的技术解决。通过对未满足的客户/患者需求、市场规模、驱动因素、动态和竞争的清晰了解，Absynth将能够选择这些机会来构建产品线。抗生素耐药性以惊人的速度增长，推动了对抗菌疫苗和抗体的需求。到2014年，细菌疫苗的市场预计将从39亿美元增长到155亿美元，人们对只有Synagis一种被许可使用的抗感染抗体产品的兴趣也在增长。金黄色葡萄球菌疫苗或抗体，销售潜力估计超过20亿美元。许多其他细菌感染缺乏疫苗或抗体，包括由C.艰难梭菌、淋病奈瑟菌引起的性传播疾病和E.杆菌Absynth的新机遇意义重大。

Absynth Biologics has successfully demonstrated an innovative approach for developing newantibacterial vaccines and antibodies. Absynth’s technology identifies proteins, essential forthe life of bacteria that harness the immune system. To date the Company has shown itsapproach can protect against infections caused by a major pathogen Staphylococcus aureus (S.aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). TheAbsynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development.A central aspect of the Absynth technology is the degree of conservation of these proteinsacross the bacterial kingdom. Consequently the same targets found in S. aureus also arepresent in many other bacterial pathogens. With this proprietary knowledge Absynth canrapidly initiate new vaccine and antibody programmes to develop a product pipeline.The objective of this project is to assess the broader market needs to prevent and treatbacterial infections, addressable by Absynth’s technology. With a clear understanding ofunmet customer/patient needs, market size, drivers, dynamics and competition, Absynth willbe able to select those opportunities to build a pipeline.Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterialvaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibodyproducts with only one, Synagis, licensed for use.There currently are no marketed S. aureus vaccines or antibodies and the sales potential isestimated to be >US $2 billion. Many other bacterial infections lack vaccines or antibodiesincluding hospital infections cause by C. difficile, sexually transmitted diseases caused by N.gonorrhoea and community-based infections caused by E. coli. The new opportunities forAbsynth are significant.